Cell Counting Global Market Report 2024

Cell counting refers to a range of techniques utilized for quantifying cells in the life sciences, facilitating diagnosis and treatment in various applications. These techniques are crucial for monitoring cell health and proliferation rates, assessing factors like immortalization or transformation, transfection or infection, seeding cells for subsequent experiments, and preparing for cell-based assays.

The primary consumables and accessories employed in cell counting include media, sera, and reagents, assay kits, microplates, accessories, and other related materials. Media, sera, and reagents play a vital role in cell culture, finding applications in areas such as cancer research, the development of biopharmaceuticals, regenerative medicine, and other research endeavors. Various products used in cell counting include spectrophotometers, single-mode and multi-mode readers, cell counters (including automated and manual variants), hemocytometers, flow cytometers, and hematology analyzers. Cell counting is widely utilized in research applications, clinical and diagnostic settings, as well as industrial applications. End-users of cell counting technologies include hospitals and diagnostic facilities, research institutions, pharmaceutical and biotechnology companies, among others.

The cell counting market research report is one of a series of new reports that provides cell counting market statistics, including cell counting industry global market size, regional shares, competitors with a cell counting market share, detailed cell counting market segments, market trends and opportunities, and any further data you may need to thrive in the cell counting industry. This cell counting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell counting market size has grown strongly in recent years. It will grow from $9.96 billion in 2023 to $10.87 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The expansion observed in the historical period can be attributed to various factors, including growth in biomedical research, increased demand for clinical diagnostics, expansion of the pharmaceutical industry, heightened focus on cancer research, and the overall increase in the aging population. These factors collectively contributed to the growth and utilization of cell counting techniques and technologies during this period.

The cell counting market size is expected to see strong growth in the next few years. It will grow to $15.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. Anticipated growth in the forecast period can be attributed to several factors, including an increasing focus on precision medicine, the growing adoption of regenerative medicine, a rise in point-of-care testing, and increased emphasis on stem cell research. Noteworthy trends expected in the forecast period encompass technological advancements, product innovations, integration of artificial intelligence (AI), adoption of automation technology solutions, and strategic collaborations within the field of cell counting.

The growth of the cell counting market is primarily attributed to the increasing prevalence of cancer globally. Factors such as lifestyle changes, unhealthy eating habits, and the lack of maintenance of a healthy body weight contribute to chronic diseases and infections, elevating the risk of cancer. Various factors like smoking, radiation, viruses, carcinogens, obesity, hormones, chronic inflammation, and inadequate exercise can lead to cancer. As the global population continues to grow, and exposure to risk factors for cancer rises, there is an escalating need for cell counting. For instance, in January 2022, the American Cancer Society reported an estimate of 1.9 million new cancer cases and 609,360 deaths from cancer in the United States for the year 2022. The increasing prevalence of cancer worldwide underscores the importance of cell counting in diagnostics and monitoring, driving the growth of the market.

The rise in chronic diseases is expected to be a significant driver for the cell counting market. Chronic diseases, lasting a year or longer and requiring ongoing medical care, are becoming increasingly prevalent globally. These diseases, characterized by complex etiologies, multiple risk factors, and extended incubation periods, necessitate regular monitoring and diagnosis. Cell counting plays a crucial role in diagnostic and monitoring processes for chronic illnesses, providing valuable information about disease progression and treatment effectiveness. Reports from HealthCentral LLC and the National Association of Chronic Disease Directors highlight that a substantial proportion of the U.S. population is affected by at least one chronic condition, emphasizing the growing need for cell counting in managing chronic diseases.

Technological advancements represent a key trend in the cell counting market. Major players in the market are actively engaged in developing innovative technological solutions to enhance their market position. Next-generation information management solutions focus on improving patient care by increasing capabilities that enhance efficiency in hospital laboratories. Bio-Rad Laboratories Inc., for example, introduced the TC20 Automated Cell Counter, featuring advanced auto-focus technology and a sophisticated cell-counting algorithm, providing accurate mammalian cell counting in less than 30 seconds. This technological innovation is contributing to the overall growth and development of the cell counting market.

Leading companies in the cell counting market are strategically focusing on introducing innovative products to cater to the evolving needs of their consumer base. One notable example is the BD FACSDiscover S8 spectral cell sorter, developed by Becton, Dickinson, and Company (BD), a prominent U.S.-based medical device manufacturer. This innovative product utilizes spectral flow cytometry and high-speed imaging technologies, enabling the sorting of cells based on their visual properties. In contrast to traditional flow cytometry, which detects specific fluorescent bands, spectral flow cytometry collects the entire spectrum of signals produced by sample arrangements. This allows for multi-parameter sorting, offering researchers a more comprehensive understanding of cells. The BD FACSDiscover S8 Cell Sorter, launched in May 2023, incorporates game-changing technologies, including BD CellView Image Technology, enabling researchers to examine detailed microscopic images of individual cells and sort them rapidly based on visual criteria. Additionally, BD SpectralFX Technology facilitates high-parameter studies with full-spectrum cell sorting, enhancing performance through a flexible optical architecture and system-aware algorithms. These advancements significantly broaden researchers' capabilities, potentially revolutionizing research and the development of cell-based therapies in areas such as drug discovery, immuno-oncology, and genomics.

In another strategic move, Danaher Corporation, a U.S.-based diagnostics science and technology company, acquired Precision NanoSystems Inc. (PNI) in June 2021 for an undisclosed amount. This acquisition, facilitated through Danaher's life sciences platform, focused on enhancing technical solutions for the creation and production of lipid nanoparticles. Precision NanoSystems specializes in developing solutions for delivering genetic therapies like mRNA. The acquisition positioned PNI as part of Danaher's Life Sciences platform, complementing existing entities such as Cytiva and Pall. This strategic move underlines the importance of staying at the forefront of technological advancements in the field of diagnostic, imaging, and cell counting solutions.

Major companies operating in the cell counting market include Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Olympus Corporation, HORIBA Ltd., Logos Biosystems Inc., Becton Dickinson and Company, GE Healthcare, Agilent Technologies Inc., BioTek Instruments Inc., DeNovix Inc., Sysmex Corporation, Nexcelom Bioscience LLC, Beckman Coulter Inc., Roche Diagnostics International Ltd., Miltenyi Biotec GmbH, AccuBioTech Co. Ltd., ChemoMetec A/S, Countstar Microscopy Systems, Luminex Corporation, NanoEnTek Inc., Partec GmbH, Advanced Instruments Inc., Analytik Jena AG, Integra Biosciences AG, Meridian Bioscience Inc., Promega Corporation, Sartorius AG

North America was the largest region in the cell counting market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell counting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cell counting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The cell counting market includes revenues earned by entities by direct total, indirect total, direct differential, and indirect differential cell counting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.